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Physiologic Response to Angiotensin
II Treatment for Coronavirus Disease
2019–Induced Vasodilatory Shock:
A Retrospective Matched Cohort Study
Daniel E. Leisman, MD, MSCR1,2; Fiore Mastroianni, MD2,3,4; Grace Fisler, MD4,5; Sareen Shah, MD4,5;
Zubair Hasan, MD3,4; Mangala Narasimhan, DO3,4; Matthew D. Taylor, MD2,4,5;
Clifford S. Deutschman, MD, MS2,4,5

Objectives: To assess the early physiologic response to angiotensin-II
treatment in patients with coronavirus disease 2019–induced respiratory failure and distributive shock.
Design: Retrospective consecutive-sample cohort study.
Setting: Three medical ICUs in New York during the coronavirus disease 2019 outbreak.
Patients: All patients were admitted to the ICU with respiratory failure
and were receiving norepinephrine for distributive shock.
Interventions: The treatment groups were patients who received
greater than or equal to 1 hour of angiotensin-II treatment. Time-zero
was the time of angiotensin-II initiation. Controls were identified using
a 2:1 hierarchical process that matched for 1) date and unit of admission; 2) specific organ support modalities; 3) age; 4) chronic lung,
cardiovascular, and kidney disease; and 5) sex. Time-zero in the control group was 21 hours post vasopressor initiation, the mean duration
of vasopressor therapy prior to angiotensin-II initiation in the treated
group.
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Measurements and Main Results: Main outcomes were trajectories
of vasopressor requirements (in norepinephrine-equivalent dose) and
mean arterial pressure. Additionally assessed trajectories were respiratory (Pao2/Fio2, Paco2), metabolic (pH, creatinine), and coagulation
(d-dimer) dysfunction indices after time-zero. We also recorded adverse
events and clinical outcomes. Trajectories were analyzed using mixedeffects models for immediate (first 6 hr), early (48 hr), and sustained (7 d)
responses. Twenty-nine patients (n = 10 treated, n = 19 control) were
identified. Despite matching, angiotensin-II–treated patients had markedly greater vasopressor requirements (mean: 0.489 vs 0.097 µg/kg/
min), oxygenation impairment, and acidosis at time-zero. Nonetheless,
angiotensin-II treatment was associated with an immediate and sustained reduction in norepinephrine-equivalent dose (6 hr model:
β = –0.036 µg/kg/min/hr; 95% CI: –0.054 to –0.018 µg/kg/min/hr,
pinteraction=0.0002) (7 d model: β = –0.04 µg/kg/min/d, 95% CI: –0.05 to
–0.03 µg/kg/min/d; pinteraction = 0.0002). Compared with controls, angiotensin-II–treated patients had significantly faster improvement in mean
arterial pressure, hypercapnia, acidosis, baseline-corrected creatinine,
and d-dimer. Three thrombotic events occurred, all in control patients.
Conclusions: Angiotensin-II treatment for coronavirus disease
2019–induced distributive shock was associated with rapid improvement in multiple physiologic indices. Angiotensin-II in coronavirus disease 2019–induced shock warrants further study.
Key Words: angiotensin II; coronavirus disease 2019; norepinephrine;
severe acute respiratory syndrome coronavirus-2 infection; shock;
vasoconstrictor agents
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atients with critical illness induced by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection
frequently develop distributive shock (1, 2). Coronavirus
disease 2019 (COVID-19) is frequently associated with cardiomyopathy (3), troponinemia, and acute kidney injury (4), as
www.ccejournal.org
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well as lymphopenia (1) and an “immunoparalysis” phenotype
(5). Norepinephrine is recommended as the first-line vasopressor to treat distributive shock in COVID-19 (weak recommendation, low-quality evidence) (6). However, norepinephrine
produces cardiovascular strain, exerts immunosuppressive
effects, and often requires profoundly high doses when used
as a single agent (7, 8). Therefore, alternative therapies to limit
norepinephrine exposure for patients COVID-19 are important
to explore.
Angiotensin-II is an U.S. Food and Drug Administrationapproved treatment for distributive shock that reduces exogenous
catecholamine requirements (8, 9). In contrast to norepinephrine,
angiotensin-II enhances T-lymphocyte and natural killer cell proliferation and function (10, 11). Angiotensin-II is also associated
with improved survival in distributive shock patients who require
renal placement therapy (12) and in those with elevated plasma
renin levels (13). Indeed, some has proposed angiotensin-II deficiency arising from SARS-CoV-2–induced endovascular damage,
and angiotensin-converting enzyme (ACE)–1 “shedding” contributes to the pathogenesis of COVID-19–induced shock (14). These
properties suggest that angiotensin-II is an appropriate alternative
to norepinephrine for the treatment of distributive shock in the
setting of COVID-19.
However, there are concerns about angiotensin-II use in
COVID-19. In rodent models, angiotensin-II signaling increases
pulmonary inflammation and lung injury (15). Further, angiotensin-II has prothrombotic properties (16), and COVID-19 appears
to induce a hypercoagulable state (17). Therefore, observational
studies to assess safety and efficacy signals of angiotensin-II in
COVID-19–associated shock are warranted prior to undertaking
randomized trials. To meet this need, we conducted a retrospective matched-cohort study of angiotensin-II use in critically ill
patients with COVID-19 and vasodilatory shock. We sought to
characterize the immediate and subsequent physiologic response
to treatment and the frequency of adverse events.

METHODS
Design
We undertook a retrospective consecutive-sample matchedcohort study of adult critically ill patients with COVID-19 treated
at three hospitals in New York between February 27 and April 24,
2020. We sought to characterize immediate and subsequent physiologic responses to angiotensin-II exposure, as well as to assess
the development of adverse events. The study was approved by the
local Institutional Review Board.
Study Timeline
For angiotensin-II patients, “time-zero” (T0) was defined as the
moment immediately prior to angiotensin-II administration. For
controls, T0 was set at 21 hours after the initiation of vasopressor
therapy. This time period was chosen because it was the average
duration of vasopressor therapy prior to angiotensin-II initiation
in the treatment group. Data were abstracted hourly for all patients
for the 6 hours following T0 and daily for the next 7 days. Adverse
events and outcomes were recorded for the entire hospitalization.
2
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Screening and Eligibility Criteria
All patients were admitted to the ICU with COVID-19–induced
acute respiratory insufficiency and were receiving norepinephrine
for clinically diagnosed distributive shock. A list of all admissions
associated with an angiotensin-II order during the study-period
was generated from the electronic medical record. The list was systematically screened by two reviewers (F.M., G.F.). Patients were
included if angiotensin-II was administered for greater than or
equal to 1 hour. To identify controls, a list of all admissions to
the same ICU within 5 days of an angiotensin-II–treated patient’s
admission date were systematically reviewed. We excluded
patients with active do-not-resuscitate orders prior to T0 or with
evidence of purely cardiogenic or hypovolemic shock at T0.
Matching Procedure
A propensity-score matching approach would have been poorly
suited to this study given the high likelihood of endogenous treatment allocation (18). We employed a 2:1 hierarchical process to
identify controls, with matching criteria selected and ranked a
priori. Eligible records were reviewed consecutively until two
controls were identified for each treated patient or the list was
exhausted. The ranked criteria were as follows:
1) Unit and date of ICU admission: Eligible controls were admitted to the same ICU within 5 days of a treated patient. We prioritized these criteria due to progressive resource limitation,
expansion of ICU care into non-ICU spaces, and rapidly fluctuating practice patterns over the study period. We reasoned
that these secular changes in practice and environment would
be hardest to identify and effectively account for if not matched
as precisely as possible.
2) Organ support: Potential controls were then exactly matched to
treated patients with respect to the following binary variables at
T0: invasive mechanical ventilation, vasopressors, renal replacement therapy (RRT), and extracorporeal membrane oxygenation.
3) Age: Eligible controls were aged within 5 years of treated
patients older than 50 years old and within 10 years of treated
patients younger than 50 years old.
4)	Comorbidities: Eligible controls–matched treated patients on
diagnoses of chronic lung (composite of chronic obstructive
pulmonary disease [COPD] or asthma), cardiovascular (composite of diabetes, hypertension, or coronary artery disease
[CAD]), or chronic kidney disease (CKD). We selected these
comorbidities because we reasoned these were highly relevant
to physiologic outcomes in relation to both COVID-19 and
angiotensin-II administration.
5) Sex: Although criteria 1–4 were obligate matching criteria, if a
list of potential controls was exhausted without identifying two
matches, the list was rereviewed for a sex-agnostic match. This
occurred for two treated patients. If a second match was not
identified after relaxing sex-match requirements, then only one
control was included. This occurred for one treated patient.
Outcomes
The main outcomes of interest were indicators of physiologic
responses to angiotensin-II. To assess cardiovascular response, we
2020 • Volume 2 • e0230
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compared the amount of vasopressor support—measured in norepinephrine-equivalent dose (8)—and the mean arterial pressure
(MAP). We assessed immediate (first 6 hr from T0), early (48 hr),
and prolonged responses (7 d). Additional physiologic trajectories
of interest were as follows: Pao2 to Fio2 ratio (P/F ratio), Paco2,
arterial pH, serum creatinine, and Sequential Organ Failure
Assessment (SOFA) score. For all measurements, the “worst”
value (e.g., lowest MAP, highest Paco2, etc.) recorded from the
time period was used.
We additionally recorded several inflammatory and immune
markers. Specifically, we abstracted serum levels of d-dimer,
C-reactive protein (CRP), ferritin, and troponin, as well as lymphocyte and monocyte counts.
Elevated plasma renin levels in patients with distributive
shock are both indicative of ACE-1 dysfunction and predictive of
response to angiotensin-II treatment (13, 19). For this reason, we
also recorded direct plasma renin levels if drawn within 24 hours
prior to T0.
As exploratory analyses we compared adverse event frequency
and patient outcomes. The only complication that was greater
among angiotensin-II–treated patients in the Angiotensin II for
the Treatment of High-Output Shock trial was the frequency of
thromboembolic complications (8, 9). Therefore, the primary
adverse event in this study was the development of any thromboembolic complication, operationalized as a composite of
deep-vein thrombosis, pulmonary embolism, limb ischemia,
myocardial infarction, ischemic stroke, mesenteric ischemia, or
circuit thrombosis for patients receiving RRT. Additional adverse
events were positive blood cultures drawn greater than 48 hours
after T0 and presence of a secondary infection. Secondary infections were considered present on the basis of antibiotic administration for a clinically documented presumed source of infection.
Clinical outcomes were mortality, vasopressor-free, ventilatorfree, and RRT-free days, where “free” indicates free of both organ
support and death.
Data Collection and Validation
A single author (F.M,) abstracted data from the chart into a standardized electronic data collection form according to a prespecified protocol. This form was piloted and fine-tuned prior to data
collection. It featured hard-stops for impossible values and confirmation requests for missing values. The abstractor was not blinded
to the study hypothesis, but outcomes often had not yet occurred
at the time of initial data collection. To ensure data fidelity, one
author (D.E.L.) reviewed each completed form in blinded fashion
for data that were possible but unlikely (e.g., a missing Paco2 level
when a Pao2 level was recorded) and returned the forms to the
abstractor with these queries highlighted.
Statistical Analysis
Continuous variables are reported as means (sd) or medians
(interquartile range), as appropriate. Categorical variables are
reported as frequencies (percentages). We built mixed-effects generalized linear models to compare physiologic trajectories over
time. Each patient was entered as a random-effect to account for
within-subject correlation. Fixed-effect independent variables
Critical Care Explorations

were treatment group, time of measurement, the interactioneffect of treatment by time, and a class variable for treated control
matches. Given that physiologic trajectory could reflect natural disease course evolution, we prespecified that the interaction
effect of time by treatment would be the primary measure of comparison because this coefficient reflects how the rate-of-change
differed between treatment groups.
Each model was iterated on two time-horizons: once over the
entire 7-day study period and once with all observations after 48
hours censored. The latter was to account for the possibility of
a Neyman bias and to focus on the early response to treatment.
For norepinephrine-equivalents and MAP, models were iterated
a third time with all observations censored after 6 hours to capture the immediate cardiovascular response to treatment. The
creatinine models were adjusted for patients’ pre hospital baseline
creatinine. When a baseline creatinine level could not be directly
ascertained, it was estimated using the modified diet in renal
disease equation as recommend by the Acute Dialysis Quality
Initiative guidelines (20).
There were no missing data for cardiovascular, arterial blood
gas, creatinine, or categorical outcomes. However, inflammatory
markers were not always measured daily. Therefore, we interpolated missing values as the point along the slope of the line between
the most recent and the subsequent measurement. Variables that
had an excess of missing data were not analyzed. We considered an
excess of missing data to be greater than 10% of patients in either
treatment group with greater than 20% missing data. All analyses
were performed in SAS: University-Edition (SAS Institute, Cary,
NC), and figures were produced with Prism-8 (GraphPad, San
Diego, CA).

RESULTS

The final analysis included 29 patients: 10 who received angiotensin-II and 19 matched-controls. The groups were balanced in
terms of demographics, comorbidities, and home medications
(Table 1). However, the angiotensin-II group appeared to be more
severely ill at T0 (Table 2). Greater cardiovascular dysfunction was
evidenced by nearly five-fold greater norepinephrine-equivalent
dose (mean: 0.49 vs 0.01 µg/kg/min) and lower MAP (69.2 vs
83.2 mm Hg) at T0. The angiotensin-II group also had worse baseline gas-exchange (P/F ratio: 165 vs 215; Paco2: 60 vs 46 mm Hg),
acidosis (pH: 7.21 vs 7.33), and SOFA scores (11.3 vs 10.2). In contrast, creatinine at T0 was similar between groups (1.8 vs 2.0 mg/
dL). The average duration of angiotensin-II treatment was 2.7 (sd:
1.5) days. All angiotensin-II–treated patients received greater than
6 hours of treatment.
Cardiovascular Response
Despite baseline differences in cardiovascular function, angiotensin-II initiation was associated with an immediate cardiovascular
response. There was no change in norepinephrine-equivalents for
the control group over the initial 6 hours (0.00 µg/kg/min/hr). In
contrast, mean norepinephrine-equivalent dose in the angiotensin-II group fell nearly 50% by 6 hours to 0.23 µg/kg/min (rate of
change: –0.04 µg/kg/min/hr; 95% CI vs controls: –0.05 to –0.02 µg/
www.ccejournal.org
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TABLE 1.

Demographic and Baseline Variables
Total
(n = 29)

Variables

Angiotensin-II
(n = 10)

Controls
(n = 19)

29

10

19

Age (yr), mean (sd)

56 (14)

54 (15)

57 (33)

Male, n (%)

19 (66)

7 (70)

12 (63)

32.5 (7.1)

32.1 (9.1)

32.7 (6.1)

14 (48)

4 (40)

10 (53)

5 (17)

2 (20)

3 (16)

10 (34)

9 (90)

9 (47)

Asthma

4 (14)

1 (10)

3 (16)

Chronic kidney disease

2 (7)

1 (10)

2 (11)

n
Demographics

Body mass index, mean (sd)
Baseline comorbidities, n (%)
Diabetes mellitus
Coronary artery disease
Hypertension

   Baseline creatinine (dg/mL), median (interquartile range)

1.06 (0.88–1.13)

1.09 (0.93–1.15)

1.06 (0.87–1.10)

Malignancy

2 (7)

0

2 (11)

Chronic obstructive pulmonary disease

1 (3)

1 (10)

0

HIV

1 (3)

0

Solid organ transplant

1 (3)

1 (10)

0

Cirrhosis

0

0

0

Chronic heart failure

0

0

0

7 (24)

3 (30)

4 (21)

   Angiotensin receptor blocker

1 (3)

1 (10)

0

   Angiotensin-converting enzyme-1 inhibitor

6 (21)

2 (20)

4 (21)

Beta blocker

6 (21)

3 (30)

3 (16)

Calcium channel blocker

4 (14)

2 (20)

2 (11)

Other antihypertensive

5 (17)

3 (30)

2 (11)

Factor-directed anticoagulation

2 (7)

1 (10)

1 (5)

Antiplatelet therapy

3 (10)

1 (10)

2 (11)

Corticosteroids

2 (7)

1 (10)

1 (5)

Immune modulator

3 (10)

2 (7)

1 (5)

1 (5)

Home medications, n (%)
Renin angiotensin aldosterone system blockade

kg/min/hr; pinteraction = 0.0002) (Fig. 1). When the modeling timehorizon was expanded to 48 hours, there was a significant reduction in norepinephrine-equivalents among controls (–0.03 µg/kg/
min/d; 95% CI: –0.06 to 0.00 µg/kg/min/d). However, the rate of norepinephrine-equivalent dose reduction was significantly greater in
the angiotensin-II group (–0.13 µg/kg/min/d; difference: –0.01 µg/
kg/min/d; 95% CI: –0.15 to –0.05 µg/kg/min/d; pinteraction = 0.0004).
Similarly, although MAP in control patients did not change
over the 6-hour time-horizon, MAP increased by 7.7 mm Hg
(1.3 mm Hg/hr; 95% CI: 0.01–2.9 mm Hg/hr; pinteraction = 0.0454)
over the first 6 hours in angiotensin-II–treated patients. The groups
did not significantly differ in MAP trajectory over 48 hours, in the
4
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setting of MAP equilibrating between groups in the first hour after
T0 (Fig. 1B). Trajectories over the 7-day study period were more
favorable in the angiotensin-II group for both norepinephrineequivalent dose (–0.04 µg/kg/min/d; 95% CI: –0.05 to –0.03 µg/
kg/min/d; pinteraction = 0.0002) and MAP (1.3 mm Hg/d; 95% CI:
0.3–2.4 mm Hg/d; pinteraction = 0.0162).
Physiologic Trajectories
We depict the trajectories of additional physiologic variables in
Figure 2. Despite greater severity at baseline, both Paco2 and pH
improved to a greater degree and more rapidly in angiotensin-IItreated patients than in controls. This effect was most pronounced
2020 • Volume 2 • e0230
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TABLE 2.

Laboratory and Treatment Variables at Time-Zero

Variables

Total

n

29

Vasopressor duration before T0 (hr), median
(interquartile range)
Mean arterial pressure (mm Hg), median (interquartile range)
Norepinephrine equivalent dose (µg/kg/hr), median
(interquartile range)
Norepinephrine, n (%)

Not applicable
78.3 (67–89)
0.232 (0.04–0.22)
28 (97)

Angiotensin-II

Controls

10

19

21.30 (6–32)

21 (21–21)

69.2 (60–81)

83.2 (68–95)

0.489 (0.06–0.81)
10 (100)

0.097 (0.03–0.15)
18 (95)

Vasopressin, n (%)

2 (6.9)

Phenylephrine, n (%)

1 (3)

0

0

0

0

8 (28)

4 (40)

4 (21)

29 (100)

10 (100)

19 (100)

Epinephrine, n (%)
Right heart failure, n (%)
Invasive mechanical ventilation, n (%)

2 (20)

0
2 (5)

Baseline Fio2, median (interquartile range)

0.59 (0.40–0.80)

Pao2 (mm Hg), median (interquartile range)

103 (76–116)

99 (73–119)

Paco2 (mm Hg), median (interquartile range)

50.8 (39–55)

60 (46–75)

pH, median (interquartile range)

7.29 (7.19–7.37)

7.21 (7.14–7.32)

7.33 (7.26–7.39)

Pao2:Fio2, median (interquartile range)

198 (134–232)

165 (119–207)

215 (142–290)

6.3 (5.5–6.8)

5.8 (5.2–6.2)

6.5 (5.9–7.0)

Tidal volume (mL/kg) , median
(interquartile range)
a

0.66 (0.40–0.80)

0.55 (0.40–0.80)
105.32 (82–114)
46 (39–50)

Respiratory rate, median (interquartile range)

25.5 (20–32)

24 (16–28)

26 (20–34)

Positive end-expiratory pressure (cm H2O),
median (interquartile range)

13.3 (10–16)

14.6 (14–18)

12.6 (10–16)

Mean airway pressure (cm H2O), median (interquartile range)

21.5 (16.5–23)

22 (17–23)

19.75 (16–24)

Peak pressure (cm H2O), median (interquartile range)

32.7 (28–37.5)

34.6 (32–37)

31.7 (27–38)

Creatinine (mg/dL), median (interquartile range)

1.95 (1.18–2.16)

1.82 (1.31–2.14)

2.00 (0.61–2.88)

Bicarbonate (mmol/L), median (interquartile range)
Base excess (mmol/L), median (interquartile range)

22.28 (20–24)
–2.5 (–5.7 to 0.9)

20.50 (18–24)

23.21 (20–25)

–4.50 (–8.5 to –0.4)

–1.38 (–5.1 to 0.9)

Renal replacement therapy, n (%)

2 (7)

1 (10)

2 (11)

Positive blood culture prior to T0, n (%)

1 (3)

0

1 (5)

Sequential Organ Failure Assessment, median
(interquartile range)

10.6 (9–12)

11.3 (9–13)

10.16 (8–11)

Lymphocyte count (K/μL), median (interquartile range)

1.26 (0.71–1.63)

1.46 (0.76–1.63)

1.16 (0.68–1.67)

Monocyte count (K/μL), median (interquartile range)

0.58 (0.23–0.84)

0.65 (0.17–0.84)

0.56 (0.23–0.88)

Platelet count (K/μL), median (interquartile range)

319 (218–380)

362 (174–433)

314 (218–342)

1,687 (722–3,652)

1,981 (1,083–2,392)

1,394 (675– 3,861)

d-dimer

(ng/mL), median (interquartile range)

Ln(d-dimer), mean (sd)

7.31 (0.86)

7.45 (0.74)

7.23 (0.94)

C-reactive protein (mg/L), median (interquartile range)

96.7 (63.9–241.7)

142.8 (87.2–270.8)

77.0 (51.2–196.3)

Ferritin (ng/mL), median (interquartile range)

895 (636–1,272)

843 (534–1,019)

895 (751–1,463)

ECMO before T0

2 (7)

1 (10)

2 (10)

ECMO after T0

1 (3)

0

1 (5)

ECMO = extracorporeal membrane oxygenation.
a
Tidal volume is reported as mL/kg of ideal body weight.
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Figure 1. Vasopressor requirements in norepinephrine-equivalent dose (NED) (A and B) and mean arterial pressure (C and D) over time in angiotensin-II
(Ang-II)–treated patients versus controls. A and B, Also shows the angiotensin-II dose in Ang-II–treated patients. Markers and error bars indicate mean and sd.
Righthand tables indicate interaction coefficients (β), their 95% CIs, and interaction p values from each of the mixed-effects models for time by treatment group.
All coefficients are standardized to reflect the difference in rates of change per day, with the control group as the referent. For example, β equals to –0.10 in (A)
indicates that the NED decreased in the Ang-II by 0.10 µg/kg/min more per day than it did in the control group over 48 hours. AT2 = angiotensin-II, pint = p
value of the interaction coefficient.

in the 48-hour time-horizon models. These models adjusted for
minute ventilation, suggesting the rapid improvement in hypercapnia and acidosis was not attributable to simultaneous changes
in ventilator management. Indeed, minute ventilation over the
initial 48 hours post T0 did not change in either group. However,
although there was no change in positive end-expiratory pressure (PEEP) among controls over 48 hours, there was a significant
reduction in PEEP among angiotensin-II–treated patients (difference: –1.8 cm H2O/d; 95% CI: –3.0 to –0.6 cm H2O/d; pinteraction =
0.0035). The P/F ratio increased 7.6 U/d more in the angiotensinII group than was noted for controls, but this difference was not
statistically significant (95% CI: –5.2 to 20.4 U/d; pinteraction = 0.24).
A significantly greater reduction in creatinine (0.18 vs 0.05 mg/
dL/d) was observed over the study period in angiotensin-II–treated
patients than in controls (95% CI of difference: –0.09 to –0.28 mg/
dL/d; pinteraction = 0.0001). In contrast to the angiotensin-II group,
creatinine increased over this period in the controls (0.05 mg/dL/d;
–0.00 to 0.10 mg/dL/d; 95% CI: 0.09–0.28 mg/dL/d; p = 0.051). In
6
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contrast to pH and Paco2, the change in creatinine trajectories was
more pronounced after the initial 48 hours. There was no difference
in creatinine level or trajectory in the first 48 hours between groups.
SOFA scores fell more rapidly in angiotensin-II–treated patients
than in controls. Similarly, d-dimer levels progressively declined in
the angiotensin-II–treated group but not in the control group.
We did not analyze troponin, CRP, ferritin, or lymphocyte
counts because the quantity of missing data exceeded what could
be reasonably imputed.
Renin Levels
Four of the 10 patients in the angiotensin-II group had a direct
plasma renin level measured between 24 and 0 hours before
angiotensin-II treatment was initiated. The levels were markedly
elevated in all four and were 963.0, 820.0, 105, and 73.5 pg/mL,
respectively (reference range: 2.5–45.7pg/mL). None of these
patients had prior exposure to ACE-1 inhibitor or angiotensin-II
receptor blocker therapy.
2020 • Volume 2 • e0230
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Figure 2. Markers and error bars indicate mean and sd. Annotations indicate interaction coefficients (β), their 95% CIs, and interaction p values from each of
the mixed-effects models for time by treatment group. β reflect the difference in daily rates of change with the control group as the referent. For example,
β equals to –0.2 in (C) indicates creatinine decreased in the angiotensin-II group by 0.2 mg/dL/d more than in controls. Paco2 is adjusted for minute ventilation.
Creatinine is adjusted for the patient’s prehospitalization baseline. d-dimer was log-transformed to correct violation of the homoscedastic error assumption for
modeling. AT2 = angiotensin-II, pint = p value of the interaction coefficient, P/F ratio = ratio of Pao2 to Fio2, SOFA = Sequential Organ Failure Assessment.

Adverse Events and Patient Outcomes
We identified three adverse thrombotic events (16%), all in
control patients, one of which occurred while the patient was
Critical Care Explorations

receiving therapeutic anticoagulation (Table 3). Blood cultures
after 48 hours were positive in five control patients (29%) and
one angiotensin-II–treated patient (10%). Hospital mortality was
www.ccejournal.org
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TABLE 3.

Treatments, Adverse Events, and Outcomes

Variables

Total

Angiotensin-II

Controls

29

10

19

Hydroxychloroquine

25 (86)

6 (60)

19 (100)

Azithromycin

13 (45)

3 (30)

10 (53)

0

0

0

18 (62)

4 (40)

14 (74)

Interleukin-6 antagonist

8 (28)

2 (20)

6 (32)

Interleukin-1 antagonist

7 (24)

1 (10)

6 (32)

15 (52)

7 (70)

8 (42)

5 (17)

3 (30)

2 (11)

3 (10)

0

3 (16)

   Deep vein thrombosis

0

0

0

   Pulmonary embolism

0

0

0

   Ischemic stroke

0

0

0

   Myocardial infarction

1 (3)

0

1 (5)

   Critical limb ischemia

1 (3)

0

1 (5)

   Mesenteric ischemia

1 (3)

0

1 (5)

0

0

0

10 (34)

3 (30)

7 (37)

6 (21)

1 (10)

5 (29)

   Gram-positive organism

2

0

2

   Gram-negative organism

4

1

3

Discharged alive

14 (48)

4 (40)

10 (53)

Vasopressor-free days

3.5 (2.5)

2.8 (2.49)

3.9 (2.5)

Ventilator-free days

0.2 (0.5)

0.3 (0.7)

0.1 (0.5)

Renal replacement therapy–free days

5.0 (3.1)

4.3 (3.5)

5.4 (2.9)

n
Other treatments

Remdesivir
Corticosteroids

Therapeutic anticoagulation (excluding initiation after a thrombotic
event if one occurred)
Antiplatelet agent
Adverse events
Thrombosis
   Any thrombotic event

    Continuous renal replacement therapy with filter clot (n = 7 at risk)
Secondary infections
   Any secondary infection
   Positive blood culture drawn > 48 hr after T0

Outcomes

All continuous variables are presented as means (sd) unless otherwise indicated. All categorical variables are presented as frequency (proportion).

similar between groups: six of 10 angiotensin-II–treated patients
(60%), and nine of 19 control patients (47%) died. Other clinical
outcomes were generally comparable between groups.

DISCUSSION
In this retrospective cohort study of COVID-19–associated distributive shock, angiotensin-II treatment was associated with an
immediate and sustained reduction in vasopressor requirements,
an increase in MAP, and improvement in several physiologic
8
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indices. Similar changes were not observed in matched controls.
This greater improvement was observed despite the angiotensin-II
group’s markedly higher severity-of-illness at T0.
Although this study is too small to provide meaningful evidence concerning binary patient outcomes, the marked decrease
in vasopressor requirements and increase in MAP within hours
of treatment initiation suggests that patients with COVID-19
and distributive shock are highly responsive to angiotensin-II.
Further, the rapid improvement in noncardiovascular measures
could suggest that the effects of angiotensin-II are not limited to
2020 • Volume 2 • e0230
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the cardiovascular system. Metabolic and respiratory improvement was most pronounced in the period that directly overlapped
with when angiotensin-II treatment was being administered for
all indices except creatinine, which is a marker that tends to lag
behind acute changes in renal function. Meaning, these diverse
physiologic changes were pronounced versus nontreated controls
and appeared to occur in close temporal association to the time of
angiotensin-II infusion.
A prior case-series from Italy described angiotensin-II use in
COVID-19–associated shock and similarly reported improvement in cardiovascular and respiratory status after treatment (21).
However, this report lacked a comparator group, limiting inference.
The potential role for renin-angiotensin-aldosterone system
(RAAS) modulation in COVID-induced critical illness remains
unclear. This uncertainty arises because elements of the RAAS,
in particular angiotensin-II, modulate different, and potentially
discrepant, pathways that may contribute to the pathobiology of
COVID-19. Indeed, some have advocated for and initiated trials
of RAAS blockade in COVID-19, whereas others have suggested
trials of angiotensin-II therapy (14, 22). The putative mechanisms
by which RAAS-blockade would benefit COVID-19–induced
critical illness include dampening angiotensin-II–mediated pulmonary inflammation and antagonizing angiotensin-II–mediated
platelet activation and factor-mediated thrombosis (22). However,
angiotensin-II initiation was not associated with a decrease in P/F
ratio in this study and was in fact associated with improvement in
hypercapnia independent of minute ventilation. Further, d-dimer,
which correlates with thrombosis and appears highly prognostic
of mortality in COVID-19 (17), decreased over the course of the
study in the treated patients but not in controls. All major thrombotic events in this study occurred in the control group.
Only a small number of patients had a plasma renin-level
measured before treatment initiation. However, renin was highly
elevated in all patients assessed, none of whom were previously
taking RAAS-blocking medications. This is consistent with the
immediate cardiovascular response to angiotensin-II treatment
we observed, as elevated renin both suggests ACE-1 dysfunction
and is associated with a “hyper-responsive” phenotype to angiotensin-II treatment in distributive shock (13, 19). The combination
of highly elevated renin, a marked cardiovascular and metabolic
response, temporally associated with treatment initiation that was
not observed in controls, and the absence of signs of worsening
coagulation or lung function supports equipoise for a randomized trial of angiotensin-II versus norepinephrine in COVID-19
patients with shock.
This study has important limitations. First, retrospective design
limits causal-inference and is prone to bias (23). We attempted to
adhere to recommendations by Kaji et al (24) for reducing bias in
chart-review with systematic review of a consecutive sample by a
single abstractor following protocolized collection procedure and
by employing multiple a priori and post hoc validation practices.
Second, this small study would have been inadequately powered to
detect all but the largest differences in dichotomous outcomes. We
particularly stress our adverse event, and clinical outcomes analyses are exploratory; we urge restraint in angiotensin-II use for
COVID-19 until randomized evidence becomes available. Third, a
Critical Care Explorations

Neyman bias could impact 7-day trajectory modeling on the basis
of early death. For this reason, we regard the shorter time-horizon
models as more reliable. Fourth, the matching process identified
controls that were markedly less ill at T0 than the treated patients.
This difference may have reflected the use of inadequately granular data for matching or treatment-endogeneity where experimental therapy was more readily applied in a nonresearch context to
patients with worse prognoses. Either scenario would be expected
to bias results in favor of the control group. Alternatively, this could
also indicate T0 for some angiotensin-treated patients overlapped
with initial resuscitation, overstating their severity of illness relative to controls. Fifth, we noted a higher frequency of therapeutic anticoagulation among patients who received angiotensin-II,
which might explain why all thrombotic events occurred in the
controls. Two of the events occurred in patients not receiving anticoagulant therapy at the time and one in a patient receiving an
infusion of unfractionated heparin. Given the emerging evidence
regarding thrombosis in COVID-19, anticoagulation therapy
even in the absence of thrombosis may become more prevalent.
Sixth, two patients in the angiotensin-II group were also receiving
vasopressin at T0, which could be a confounder.
Larger, future studies should consider strategies to account for
these key confounders. However, given the numerous potential
sources of bias and the limited use of angiotensin-II in COVID-19
to date, small, randomized studies may provide a more efficient
and informative approach than larger observational analyses.

CONCLUSIONS

Angiotensin-II treatment in COVID-induced distributive shock is
associated with rapid reduction in vasopressor requirements and
improvement in multiple physiologic indices. Angiotensin-II in
COVID-19 shock warrants further study.
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